Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
Recruiting · NCT02431845 · Interventional (participants receive a specific treatment) · Lead sponsor: Severance Hospital
View the official record on ClinicalTrials.gov →Interventions studied
SSRIs
What this trial is about
The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.
Who can take part
Age range
19 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- age 19\~ 70
- OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV)
- drug naive or drug free for more than 3 months
Exclusion criteria
- any neurological disorder
- comorbid psychotic disorders
- alcohol or other substance dependence within past 6 months
- any evidences for brain diseases
Where it is running
1 location listed.
- Yonsei Univ. Health System Severance Hospital - Seoul, South Korea